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Abstract
Introduction
The effect of HCV infection on HIV disease progression remains unclear; the effect of HCV
infection duration on HIV disease progression is unknown.
Methods
We used data from a cohort of HIV seroconverters to investigate the effect of HCV infection
duration on time from HIV seroconversion to CD4 <350cells/mm3, AIDS or death, censoring
at the earlier of cART initiation or last clinic visit, adjusting for confounders and splitting data
into follow up periods from HIV seroconversion (<2, 2–4 and >4 years). We additionally
compared CD4 cell decline following HCV infection to that of mono-infected individuals with
similar HIV infection duration by fitting a random effects model. In a separate analysis, we
used linear mixed models to we examine the effect of HCV infection and its duration on CD4
increase over 48 weeks following cART.
Results
Of 1655 individuals, 97 (5.9%) were HCV co-infected. HCV<1 year was associated with a
higher risk of endpoint in each follow-up period from HIV seroconversion (HR [95% CI] 2.58
[1.51, 4.41], p = 0.001; 3.80 [1.20, 12.03], p = 0.023; 2.03 [0.88, 4.71], p = 0.098 for <2, 2–4
and >4 years respectively), compared to mono-infected individuals. However, we found no
evidence of an association for those with HCV>2 years (all p>0.89). Individuals experienced
a somewhat greater decrease in CD4 count following HCV infection lasting 13 months,
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relative to individuals with HIV alone, (estimate = -3.33, 95% CI [-7.29, 0.63] cells/mm3 per
month, p = 0.099). Of 1502 initiating cART, 106 (7.1%) were HCV co-infected, with no evi-
dence of HCV duration at cART being associated with immunological response (p = 0.45).
Conclusions
The impact of HCV co-infection on HIV disease progression appears to be restricted to the
first year after HCV infection.
Introduction
The impact of Hepatitis C Virus (HCV) on Human Immunodeficiency Virus (HIV) disease
progression remains unclear. Due to the shared routes of transmission, 25–30% of HIV positive
individuals are co-infected with HCV globally [1] and 9% in the UK [2].
Studies examining whether HCV affects HIV disease progression in the absence of combi-
nation antiretroviral therapy (cART) have generally been restricted to examining the effect on
all-cause mortality, and reported no evidence of an effect [3–9]. However, given HIV-related
causes of death are less common in co-infected individuals [9], investigating all-cause mortality
may mask the effect of HCV on HIV-specific causes of death. Therefore it remains unclear
whether co-infection affects HIV disease progression.
Given that CD4 cell count decreases in the presence of an opportunistic infection [10],
HCV infection may be expected to affect CD4 cell decline in HIV positive individuals, given
that HCV infection acts as an opportunistic infection in HIV positive individuals [11]. How-
ever, the immunological response to HCV infection may be longer-lasting, as HCV is a chronic
disease. Understanding CD4 cell evolution in co-infected individuals is important given the
increased incidence of HCV in HIV positive men who have sex with men (MSM) since 2005
[12, 13].
Furthermore, it is unclear how HCV affects immunological response to cART as, although
the majority of studies, including a meta-analysis, report worse immunological response for
co-infected individuals [4, 14, 15], some studies have found no such effect [5, 16–19]. The dif-
ference in these findings may be due to duration of HCV infection at cART initiation for co-
infected individuals, as longer HCV infection duration may have a more profound effect on
CD4 response. The relationship between the two viruses is important to understand as it may
guide the optimal time of treatment initiation for co-infected individuals.
We aimed to examine the effect of HCV infection duration on HIV disease progression dur-
ing ART-naïve follow-up, and on CD4 cell evolution following the initiation of cART. We used
a national cohort of individuals with well-estimated dates of HIV seroconversion for whom we
also estimated timing of HCV infection.
Methods
The UK HIV Seroconverters Cohort is a national cohort of individuals whose time of HIV
seroconversion has been reliably estimated. The cohort has been described in full elsewhere
[20] but, briefly, the main inclusion criterion is that individuals have a negative and a positive
HIV test at most 12 months apart. The cohort was set-up in 1994 and is followed up annually
by collecting data from routine clinic visits.
Additional HCV data were obtained by matching patients from the UK HIV Seroconverters
Cohort to data from the Sentinel Surveillance Study of Hepatitis and HIV testing in England, a
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study that collects information on hepatitis C testing carried out in 21 participating sentinel
centres in the UK [21].
Ethics Statement
TheWest Midlands – South Birmingham National Research Ethics Service specifically
approved the study (04/G2707/155). Written informed consent was obtained from all partici-
pants enrolled after 2005. The ethics committee did not require written consent from partici-
pants already enrolled at that stage. No incentives were given for participation in the study.
Statistical methods
Natural history. We examined whether HCV infection (Polymerase Chain Reaction
(PCR) positive, or antibody positive, in the absence of PCR results) was associated with time to
a composite endpoint of CD4<350 cells/mm3, AIDS defining condition, or death. In Cox pro-
portional hazards models, we investigated the impact of HCV co-infection on time from HIV
seroconversion to the composite endpoint, censoring at the earlier of cART initiation or date
last seen before 6th August 2014. HCV infection was fitted as a binary time-updated covariate
in the model, allowing for clearing HCV. In multivariable analyses, we adjusted for age group
(per 10 year increase), sex, diagnosis during acute HIV infection, risk group and decade of HIV
seroconversion. We considered individuals to have entered the risk set once their HCV status
was known. Therefore, individuals were excluded from the analysis if they had unknown HCV
status throughout follow-up.
In order to examine the effect of HCV infection duration on time to the composite end-
point, we first fitted a Cox proportional hazards model including an interaction term between
HCV duration and follow-up time to determine whether any effect of HCV duration varied
over time from HIV seroconversion. As the interaction term was of borderline significance
(p = 0.086), we split the data into follow-up periods (2, 2–4,>4 years from HIV seroconver-
sion) to ensure HCV infected individuals were being compared to individuals with similar
duration of HIV infection. We then fitted 3 Cox proportional hazards models. Duration of
HCV infection was treated as a time-updated variable (1 year, 1–2 years,>2 years, and HCV
uninfected).
In sensitivity analyses, we excluded CD4 measurements from the first 3 months after HIV
seroconversion as CD4 cell count around that time are known to fluctuate widely [22]. Addi-
tionally, anti-HCV treatment was not recorded, so in order to allow for the possible short-term
effect on CD4 cell count, we repeated the analysis insisting on a confirmed CD4 cell count
<350 cells/mm3 as part of the composite endpoint, with an interval of>6 months between the
two CD4 measurements. As individuals with faster decline may be more likely to initiate cART
and, therefore, have censored follow-up, we repeated the analysis but included initiation of
cART as a component of the composite endpoint. Finally, we repeated the analysis but
excluded individuals who only had antibody positive HCV results and no PCR data.
We also investigated ART-naïve dynamics of CD4 cell count evolution by comparing CD4
cell decline of co-infected individuals following estimated HCV infection date to that of mono-
infected individuals with similar duration of HIV. This was done by fitting a random effects
mixed model with a knot, comparing the CD4 count following HCV infection to CD4 counts
of HIV-monoinfected individuals with a CD4 measurement taken at a similar (<30 days) time
point after HIV seroconversion. We adjusted for HCV status and the interaction between
HCV status and time, as well as duration of HIV at baseline, age group (per 10 year increase),
sex, diagnosis during acute HIV infection, risk group and decade of HIV seroconversion. We
established the most appropriate time point to place the knot by choosing the model based on
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Akaike Information Criterion (AIC). For HCV co-infected individuals to be included in this
analysis, they were required to have evidence of HCV infection (HCV negative followed by a
positive HCV test) and at least 1 CD4 cell measurement after HCV infection and before cART
initiation.
Response to cART. We investigated the impact of HCV infection at cART initiation
on immunological recovery by fitting random effects mixed models examining CD4 count
from cART initiation over 48 weeks of follow-up. In multivariable analyses, we adjusted for
duration of HIV at cART initiation, HIV test interval, age group at cART initiation (per 10
year increase), sex, decade of cART initiation and risk group, as well as baseline CD4 count.
A baseline reading was defined as any reading (or the mean if>1 reading) 3 months before to
2 weeks after cART initiation. The impact of duration of HCV at cART initiation on immuno-
logical response to cART was analysed by fitting the same model but with duration of HCV
infection as a continuous variable instead of HCV infection as a binary variable. We included
any individual with known HCV status with at least one baseline measurement and two fol-
low-up CD4 measurements within 48 weeks from cART initiation. In a sensitivity analysis, we
repeated the analysis but restricted to virally suppressed individuals, in order to compare indi-
viduals with and without HCV who are likely to have been adherent.
As information on HCV status was not always recorded, in all analyses we estimated HCV
seroconversion dates based on the assumption that individuals received annual HCV tests
from 2003 onwards, when annual testing for HIV positive individuals was recommended in
the UK [23]. Table 1 summarises how this assumption was implemented for estimating HCV
seroconversion dates. Additionally, we assumed that individuals with previous evidence of
HCV co-infection who subsequently had two consecutive HCV negative PCR tests to have
cleared HCV infection. In sensitivity analyses, we repeated all analyses without assumptions
about annual HCV testing for individuals with missing HCV status. We instead regarded
each individual’s HCV status as unknown until their first recorded HCV test, then assumed
their HCV status changed on the day of the HCV test. In all analyses, we defined cART as
any ART regimen started after 1st January 2000; before 1st January 2000, cART was defined
as a 3 drug ART regimen containing drugs from 2 different classes, or 3 nucleoside reverse
transcriptase inhibitors (NRTIs), provided Tenofovir or Abacavir were taken as part of that
regimen.
Table 1. Assumptions around HCV infection date for HCV co-infected individuals in the UKR Register of HIV seroconverters.
HIV seroconversion
Date*
First HCV positive Test Assumed date of HCV infection
Before 01 January 2003 Before HIV seroconversion HIV seroconversion date
Later than or on the day of HIV
Seroconversion and before 01 January 2003
Midpoint of last negative and ﬁrst positive HCV test dates. If no negative test,
then date of ﬁrst positive test.
Later than or on the day of HIV
Seroconversion and after 01 January 2003
Midpoint of last negative and ﬁrst positive HCV test dates, unless tests >1 year
apart – in which case the midpoint of last assumed negative test date (annually
from 01 January 2003 onwards) and ﬁrst positive test.
Later than or on 01
January 2003
Before HIV seroconversion Midpoint of last negative and ﬁrst positive HCV test dates. If no negative test,
then date of ﬁrst positive test.
Later than or at the same time as HIV
Seroconversion
Midpoint of last negative and ﬁrst positive HCV test dates, unless tests are >1
year apart – in which case the midpoint of last assumed negative test (annually
1 year after seroconversion date onwards) and ﬁrst positive test.
*We assumed that routine testing for HIV positive individuals was taking place from 2003 according to BHIVA guideline
doi:10.1371/journal.pone.0132772.t001
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Results
Natural history
Of 1655 individuals eligible for the study, 1558 were HCV negative throughout follow-up and
97 (5.9%) had evidence of HCV infection at any time during follow-up; 42 with PCR positive
tests, the remainder with antibody positive tests. Median (IQR) follow-up time until censoring
was 1.16 (0.33, 3.27) years. HCV uninfected individuals were more likely to be male (94.8% vs.
80.4%), less likely to be people who inject drugs (PWID) (0.3% vs. 28.9%) and more likely to
have seroconverted in later years (median [IQR] year of seroconversion 2006 [2002, 2010] vs.
2000 [1994, 2006]) compared to HCV co-infected individuals (Table 2). The composite end-
point was reached by 875 (56.2%) individuals who were HCV negative throughout follow-up
(14 deaths, 21 AIDS defining illnesses, 840 CD4<350 cells/mm3) and 68 (70.1%) individuals
who were HCV infected at any time up until the event/censoring date (1 death, 2 AIDS defin-
ing illness, 65 CD4<350 cells/mm3). Follow-up for 574 individuals was censored due to cART
initiation (550 HCV negative vs. 24 HCV positive).
Individuals with HCV infection were more likely to reach the composite endpoint (HR =
1.57, 95% CI: [1.14, 2.16], p = 0.006). Becoming HIV-positive after 2010 was associated with a
higher risk of endpoint (HR = 2.02, 95% CI: [1.15, 3.54], p = 0.014), while PWID had lower
risk of endpoint (HR = 0.50, 95% CI: [0.30, 0.84], p = 0.010).
Table 3 shows results from analyses examining HCV duration by follow-up period. In each
period, individuals with HCV infection<1 year had a higher risk of reaching the composite
endpoint than individuals with HIV infection alone (HR [95% CI] 2.58 [1.51, 4.41], p = 0.001;
3.80 [1.20, 12.03], p = 0.023; 2.03 [0.88, 4.71], p = 0.098 for<2, 2–4 and>4 years respectively).
Individuals with 1–2 years HCV infection also had a higher risk of reaching the endpoint, but
only for those with 2–4 years of HIV infection (HR [95% CI] 0.59 [0.23, 1.51], p = 0.271; 3.56
[1.91, 6.62], p<0.001; 1.43 [0.34, 5.90], p = 0.624 for<2, 2–4 and>4 years respectively). There
was no evidence that individuals with HCV for>2 years were at greater risk of reaching the
endpoint than individuals with HIV mono-infection (HR [95% CI] 1.00 [0.31, 3.24], p = 0.994;
0.95 [0.45, 1.99], p = 0.888 for 2–4 and>4 years respectively).
Table 2. Baseline characteristics of HIV seroconverters by HCV infection status.
HCV negative N = 1558 HCV positive* N = 97 Total N = 1655
Male 1477 (94.8%) 78 (80.4%) 1555 (94.0%)
Risk group: MSM** † 1406 (90.2%) 60 (61.9%) 1466 (88.6%)
MSW†† 124 (8.0%) 7 (7.2%) 131 (7.9%)
PWID††† 4 (0.3%) 28 (28.9%) 32 (1.9%)
Unknown/other 24 (1.5%) 2 (2.1%) 26 (1.6%)
Ethnicity: White 1377 (88.4%) 77 (79.4%) 1454 (87.9%)
Black African 36 (2.3%) 0 (0.0%) 36 (2.2%)
Unknown/other 145 (9.3%) 20 (20.6%) 165 (10.0%)
Diagnosis during acute HIV infection*** 91 (5.8%) 6 (6.2%) 97 (5.9%)
Year of HIV seroconversion: median (IQR) 2006 (2002, 2010) 2000 (1994, 2006) 2006 (2001, 2010)
Age at HIV seroconversion: median (IQR) 32.4 (26.9, 40.4) 31.5 (25.5, 37.9) 32.4 (26.9, 40.2)
*Evidence of HCV co-infection at any time up to time of the event/censoring date
**Includes 5 individuals who are also PWID
*** HIV positive test and negative test within 30 days of each another
† Sex between men
††Sex between men and women
†††People who inject drugs
doi:10.1371/journal.pone.0132772.t002
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The results from all 5 sensitivity analyses investigating the impact of HCV infection dura-
tion on HIV disease progression remained qualitatively unchanged (data not shown).
Investigating CD4 cell decline following HCV infection, 63 HCV infected individuals and
1720 HCV uninfected individuals were included in the analysis. The model with the lowest
AIC was one with a knot placed at 13 months after HCV infection. There was borderline evi-
dence to suggest that in the first 13 months after HCV infection, individuals with HCV experi-
enced greater CD4 decline per month than individuals without HCV infection (estimate =
-3.33, 95% CI [-7.29, 0.63] cells/mm3 per month, p = 0.099). This is equivalent to a fall over 13
months of 43.29 cells/mm3 more for an individual with HCV infection compared to an individ-
ual with HIV mono-infection. After 13 months, there was evidence of CD4 recovery in individ-
uals with HCV co-infection and their CD4 count increased per month relative to individuals
without HCV (estimate = 3.99, 95% CI [1.48, 6.50] cells/mm3 per month, p = 0.002). Fig 1
shows predicted CD4 cell evolution over 2 years after HCV infection for a 20–30 year old
MSM that HIV seroconverted after 1st January 2010.
Response to cART
Of 1502 individuals eligible for analysis, 106 (7.1%) were HCV positive at cART initiation.
HCV negative individuals were more likely to be male (94.7% vs. 77.4%), to seroconvert in
later years (median [IQR] year of HIV seroconversion 2004 [1999, 2009] vs. 1994 [1987,
2001]), to have a shorter duration of HIV at cART initiation (median years [IQR] 2.35 [0.76,
5.44] vs 7.33 [2.78, 13.47]), to have higher baseline CD4 cell counts (median [IQR] 323.1
[242.4, 443.0] vs. 258.7 [165.5, 370.0] cells/mm3), and less likely to be PWID (0.6% vs. 48.1%)
compared to co-infected individuals (Table 4).
HCV co-infected individuals experienced lower CD4 increase following cART initiation
(estimate = -0.90, 95% CI [-1.81, 0.01] cells/mm3 per week, p = 0.053) equivalent to 43.28 [95%
CI 87.10, -0.54] cells/mm3 lower over 48 weeks. Individuals starting cART in later years were
more likely to have a better CD4 cell response than individuals who started cART before 2000
(estimate [95% CI] = 38.1 [16.7, 59.4], p<0.001; 46.5 [23.0, 70.0], p<0.001 for 2000–2010 and
>2010 compared to pre-2000, respectively). As expected, higher baseline CD4 count was asso-
ciated with higher CD4 cell gains (estimate = 0.94 per cell, 95% CI [0.90, 0.98] cells/mm3,
Table 3. Effect of HCV co-infection on time from HIV seroconversion to CD4<350 cells/mm3, AIDS or death by HCV infection status and HCV infec-
tion duration: UK Register of HIV seroconverters.
Follow-up time (years) HCV infection status/duration (years)
HCV uninfected <1 1–2 >2 years
<2: Number of individuals (Number of events) 1448 (471) 34 (16) 18 (6) 19 (0)
Unadjusted hazard ratio [95% CI] 1 2.91 [1.77, 4.79] 0.80 [0.36, 1.79] **
Adjusted* hazard ratio [95% CI] 1 2.58 [1.51, 4.41] 0.59 [0.23, 1.51] **
2–4: Number of individuals (Number of events) 507 (196) 4 (3) 13 (11) 20 (6)
Unadjusted hazard ratio [95% CI] 1 3.53, [1.13, 11.06] 3.48 [1.89, 6.40] 0.69 [0.31, 1.56]
Adjusted* hazard ratio [95% CI] 1 3.80 [1.20, 12.03] 3.56 [1.91, 6.62] 1.00 [0.31, 3.24]
>4: Number of individuals (Number of events) 285 (208) 11 (6) 3 (2) 20 (18)
Unadjusted hazard ratio [95% CI] 1 2.06 [0.90, 4.70] 1.18 [0.29, 4.76] 0.62 [0.37, 1.01]
Adjusted* hazard ratio [95% CI] 1 2.03 [0.88, 4.71] 1.43 [0.34, 5.90] 0.95 [0.45, 1.99]
*Adjusted for sex, age at cART (per 10 years), diagnosis during acute HIV infection, decade of HIV seroconversion and risk group.
**Not possible to estimate the hazard ratio because the estimation algorithm did not result in convergence towards an estimate.
doi:10.1371/journal.pone.0132772.t003
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p<0.001) and longer HIV infection duration at cART initiation was associated with lower CD4
cell counts following cART initiation (estimate = -0.08 per week, 95% CI [-0.11, -0.05] cells/
mm3, p<0.001). The effect of HCV co-infection was stronger when restricting the analysis to
individuals with viral suppression (estimate [95% CI] = -1.52 [-2.75, -0.28] cells/mm3 per
week, p = 0.016).
We found no overall evidence to suggest that HCV infection duration at cART initiation
was associated with CD4 cell gains over 48 weeks, even after restricting to individuals who
were virally suppressed (p = 0.45 and p = 0.27 respectively).
Results from all sensitivity analyses where assumptions about annual HCV testing were
dropped remained qualitatively unchanged, with the exception of the CD4 cell count following
HCV infection, which gave similar estimates but without a significant association, likely due to
a lack of statistical power (data not shown).
Discussion
This is the first study to investigate the effect of HCV infection duration on HIV disease pro-
gression and response to cART. We found that, in the absence of cART, there is evidence of
Fig 1. Predicted declines in CD4 counts comparing HCV infected individuals to those with similar HIV duration without HCV infection.
doi:10.1371/journal.pone.0132772.g001
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shorter time to our composite endpoint for HCV-infected, compared to HCV uninfected indi-
viduals. However, this seems to be restricted to the first year or so following HCV infection.
This is supported by our finding of greater CD4 loss for HCV co-infected individuals in the
first thirteen months after HCV infection, which is followed by compensatory CD4 cell
recovery.
These findings can, therefore, be regarded as consistent with studies which have reported no
impact of HCV co-infection on all-cause mortality [3–9]. They may also explain why some
studies have found no overall effect of HCV infection on CD4 cell evolution [3, 7], as any such
effect is likely only in the first year following HCV infection. One study reported no overall dif-
ference in immunological progression between HCV co-infected and HIV mono-infected indi-
viduals, but significantly poorer progression for co-infected individuals with CD4>600 cells/
mm3 [6]. Of interest, the HCV co-infected population in that study were largely PWID, who
are likely to have contracted HCV infection at the same time as HIV and would, therefore,
have had short HCV infection duration. Our finding of more rapid CD4 decline only in the
first year of HCV infection would tend to lend support to this finding.
We found some evidence of different initial decline in CD4 cell count while ART-naïve fol-
lowing HCV infection. This may be due to the suggested higher levels of T-cell activation upon
contracting HCV [24] and, therefore, an increased initial replication rate for both HCV and
HIV.
On initiation of cART, we also found that HCV co-infected individuals have lower immu-
nological gains than HIV mono-infected individuals. Certainly there is evidence that HCV
may replicate in the same cells as HIV-1 [25], which may account for these observed lower
CD4 cell gains. Our finding is supported by a number of studies [4, 9, 14], including a meta-
analysis [15], although one study suggested there is no immunological impact of HCV infec-
tion following cART initiation [5]. The reasons for discrepancies in findings are unclear, but it
has been suggested that duration of HCV may have been responsible for differences in findings
[5]. However, we found no evidence to suggest that CD4 cell count rise following cART
Table 4. Baseline characteristics of HIV seroconverters initiating cART by HCV status.
HCV Negative N = 1396 HCV Positive* N = 106 Total N = 1502
Male 1322 (94.7%) 82 (77.4%) 1404 (93.5%)
Risk Group: MSM† 1253 (89.8%) 49 (46.2%) 1302 (86.7%)
MSW†† 119 (8.5%) 5 (4.7%) 124 (8.3%)
PWID††† 8 (0.6%) 51 (48.1%) 59 (3.9%)
Unknown/other 16 (1.1%) 1 (0.9%) 17 (1.1%)
Ethnicity: White 1226 (87.8%) 72 (67.9%) 1298 (86.4%)
Black African 47 (3.4%) 0 (0.0%) 47 (3.1%)
Unknown/other 123 (8.8%) 34 (32.1%) 157 (10.5%)
Years between HIV seroconversion and cART initiation: Median (IQR) 2.35 (0.76, 5.44) 7.33 (2.78, 13.47) 2.51 (0.84, 5.82)
Years HIV test interval: median (IQR) 0.58 (0.29, 0.97) 0.84 (0.38, 1.27) 0.60 (0.29, 1.00)
Year of seroconversion: Median (IQR) 2004 (1999, 2009) 1994 (1987, 2001) 2004 (1999, 2008)
Age at ﬁrst cART Median (IQR) 37.11 (30.76, 44.23) 37.48 (33.55, 42.33) 37.13 (30.90, 44.04)
Baseline CD4: Median (IQR) 323.1 (242.4, 443.0) 258.7 (165.5, 370.0) 320.0 (238.5, 438.3)
*Evidence of HCV co-infection at cART initiation
† Sex between men
††Sex between men and women
†††People who inject drugs
doi:10.1371/journal.pone.0132772.t004
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initiation was associated with HCV infection duration. It is likely, therefore, that this finding
was due to other factors such as late ART initiation or different ART regimens.
There are a number of implications for clinical practice as a result of these findings. First,
for patients presenting with recently-acquired HCV infection, a sustained fall in CD4 cell
count is expected before recovering in the absence of cART. There is, therefore, no specific rea-
son to preferentially initiate immediate cART, as in line with current guidelines [26]. This may
be an important finding at a time when HCV incidence amongst HIV positive individuals is
known to have increased [12, 13]. Secondly, individuals with HCV co-infection will have
slower CD4 cell count recovery following cART initiation, regardless of duration of HCV infec-
tion duration. There is no immediate need, therefore, to start rather than delay cART initiation
based on concerns of optimal CD4 cell recovery.
There are a number of limitations to our study, the most important being that we have lim-
ited/no information on HCV treatment and it may be argued that the drop in CD4 count
observed in the first 13 months following HCV infection merely reflects the effect on CD4 cell
count of anti-HCV treatment [27]. However, anti-HCV treatment is, at most, of 24-week dura-
tion [28] and, although we could not account for this in analysis, we performed a sensitivity
analysis requiring a confirmed CD4 cell count<350 cells/mm3>6 months after the initial
reading as part of the composite endpoint. Furthermore, the sustained decrease in CD4 count
of 13 months is longer than the 24-week duration of anti-HCV treatment. Finally anti-HCV
treatment uptake is known to have been low during the study period [29–30], at 17% in the UK
[31]. A further limitation is that the HCV infection dates were estimated using a number of
assumptions based on annual HCV testing in UK clinics. These assumptions were removed in
sensitivity analyses and findings remained qualitatively unchanged.
In conclusion, we found no evidence to suggest that HCV co-infection influences HIV dis-
ease progression beyond the initial time of co-infection with HCV. A drop in CD4 cell count at
that stage is expected, which is sustained for about a year. HIV-HCV co-infected individuals
however, experience poorer CD4 gains upon initiation of cART, regardless of duration of HCV
at cART initiation.
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